GlassScriptPhysician profile
Veletta Brown
NPI 1487835732
$3,129.09
in general payments reported to CMS, 2019-2025
28 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $376 · 2023: $479 · 2024: $874 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,561.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $857.95 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $400.34 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $220.61 | 2023-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $172.70 | 2021-2025 | Tavneos |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $134.75 | 2022-2024 | Nucala |
| Vanda Pharmaceuticals INC. | $125.00 | 2025 | Fanapt |
| Alkermes, INC. | $116.41 | 2023-2025 | Vivitrol, Vivitrol |
| Abiomed | $108.34 | 2025 | |
| Corcept Therapeutics | $98.57 | 2024-2025 | Korlym |
| Gilead Sciences, INC. | $86.12 | 2023-2024 | |
| Medtronic, INC. | $80.76 | 2022 | |
| Lilly USA, LLC | $79.90 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Neurelis, INC. | $72.70 | 2024 | Valtoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.28 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $52.24 | 2021 | |
| Abbott Laboratories | $47.98 | 2024 | Cardiomems |
| Merck Sharp & Dohme LLC | $43.28 | 2021-2023 | Vaxelis, Gardasil 9, Pneumovax 23 |
| Exact Sciences Corporation | $37.27 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $34.73 | 2024 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $33.40 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $28.62 | 2021 | |
| Cipher Pharmaceuticals US LLC | $15.87 | 2025 | Natroba, Spinosad |
| Impel Pharmaceuticals INC. | $15.75 | 2022 | |
| Qiagen, LLC | $14.11 | 2022 | |
| Amarin Pharma, INC. | $13.04 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $12.66 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veletta Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.